Antipsychotic

Antipsychotics, also known as neuroleptics or major tranquilizers, are a class of psychotropic medication primarily used to manage psychosis, particularly in schizophrenia and bipolar disorder, by modulating neurotransmitter activity in the brain.

Medical Uses

Antipsychotics are most frequently prescribed for the treatment of schizophrenia and schizoaffective disorder, where they are effective in reducing positive symptoms such as hallucinations, delusions, and disorganized thinking. They are also a cornerstone in the management of bipolar disorder, utilized both for acute manic or mixed episodes and as maintenance therapy to prevent relapse. Beyond these primary indications, certain atypical antipsychotics are approved as adjunctive treatments for major depressive disorder when standard antidepressants are insufficient. Additionally, they may be used off-label or in specific clinical scenarios to manage severe agitation, Tourette syndrome, irritability associated with autism spectrum disorder, and psychotic symptoms in severe Alzheimer's disease, although the latter carries significant safety warnings.

Classification

Antipsychotics are broadly categorized into three generations based on their pharmacological profiles and historical development.
First-generation antipsychotics (FGAs), or typical antipsychotics, include medications such as haloperidol and chlorpromazine. They are characterized by a high affinity for dopamine D2 receptors and a higher risk of extrapyramidal side effects.
Second-generation antipsychotics (SGAs), or atypical antipsychotics, such as risperidone, olanzapine, and quetiapine, generally exhibit a lower affinity for D2 receptors and a higher affinity for serotonin 5-HT2A receptors. They were initially thought to have a lower risk of motor side effects but are associated with significant metabolic adverse effects.
Third-generation antipsychotics, sometimes referred to as dopamine system stabilizers or partial agonists, include aripiprazole and brexpiprazole. These agents act as partial agonists at D2 receptors, aiming to stabilize dopamine levels rather than simply blocking them, which may offer a more favorable side effect profile regarding both motor and metabolic issues.

Mechanism of Action

The exact mechanism by which antipsychotics alleviate psychotic symptoms is not entirely understood, but it is heavily linked to the dopamine hypothesis of schizophrenia. Typical antipsychotics primarily exert their therapeutic effects by antagonizing dopamine D2 receptors in the mesolimbic pathway of the brain, which is thought to mediate positive psychotic symptoms. However, blockade of D2 receptors in the nigrostriatal pathway leads to extrapyramidal symptoms, while blockade in the tuberoinfundibular pathway causes hyperprolactinemia.
Atypical antipsychotics combine D2 antagonism with serotonin 5-HT2A receptor antagonism. The blockade of 5-HT2A receptors is believed to mitigate the extrapyramidal side effects associated with D2 blockade and may contribute to efficacy against negative and cognitive symptoms of schizophrenia by increasing dopamine release in the mesocortical pathway. Furthermore, many antipsychotics interact with histamine, alpha-adrenergic, and muscarinic receptors, which largely accounts for their diverse side effect profiles, including sedation, orthostatic hypotension, and anticholinergic effects.

Adverse Effects

The adverse effect profile of antipsychotics varies significantly between classes and individual agents. First-generation antipsychotics are notorious for causing extrapyramidal symptoms (EPS), which include acute dystonia, akathisia, parkinsonism, and the potentially irreversible tardive dyskinesia following long-term use. They also carry a risk of neuroleptic malignant syndrome, a rare but life-threatening neurological emergency.
Second-generation antipsychotics have a lower incidence of EPS but are strongly associated with metabolic syndrome. This includes significant weight gain, dyslipidemia, insulin resistance, and an increased risk of type 2 diabetes mellitus. Olanzapine and clozapine are particularly noted for these metabolic risks. Clozapine also carries a unique risk of agranulocytosis, necessitating strict, regular blood monitoring.
Other common side effects across various antipsychotics include sedation, orthostatic hypotension, anticholinergic effects (such as dry mouth, constipation, and blurred vision), and hyperprolactinemia, which can lead to galactorrhea, amenorrhea, and sexual dysfunction. Furthermore, antipsychotics can prolong the QT interval on an electrocardiogram, increasing the risk of potentially fatal cardiac arrhythmias.

Pharmacokinetics

Most antipsychotics are well-absorbed orally, though they often undergo significant first-pass metabolism in the liver, leading to variable bioavailability. They are highly lipophilic, allowing them to easily cross the blood-brain barrier and distribute widely into body tissues, including adipose tissue. Antipsychotics are extensively metabolized in the liver, primarily by the cytochrome P450 enzyme system, particularly CYP2D6, CYP1A2, and CYP3A4. Genetic polymorphisms in these enzymes can lead to significant interindividual variability in drug metabolism, necessitating dose adjustments in poor or ultra-rapid metabolizers. The metabolites are predominantly excreted via the urine and feces. Due to their lipophilicity and tissue binding, many antipsychotics have long elimination half-lives, which facilitates once-daily dosing and the formulation of long-acting injectable depot preparations for patients with poor medication adherence.

History

The history of antipsychotics began in the early 1950s with the synthesis and clinical introduction of chlorpromazine, initially developed as an antihistamine and surgical anesthetic adjunct. Its profound calming effect on psychiatric patients revolutionized the treatment of schizophrenia and catalyzed the deinstitutionalization movement, allowing many patients to be treated in outpatient settings. This discovery spurred the development of numerous other typical antipsychotics, such as haloperidol, throughout the 1960s and 1970s.
The limitations of typical antipsychotics, particularly their severe neurological side effects and lack of efficacy against negative symptoms, drove the search for better alternatives. Clozapine, introduced in the 1970s but restricted due to agranulocytosis, was later recognized as having superior efficacy without causing severe EPS, establishing the prototype for atypical antipsychotics. The 1990s saw the widespread introduction of newer SGAs like risperidone and olanzapine, which dominated the market for decades. More recently, the focus has shifted toward partial agonists and novel mechanisms to improve both tolerability and functional outcomes for patients.

Society and Culture

The use of antipsychotics is intertwined with significant social and cultural debates. The advent of these medications facilitated the deinstitutionalization of psychiatric patients, shifting care from large asylums to community-based settings. However, this transition was often underfunded, leading to issues such as homelessness and incarceration among the severely mentally ill.
In contemporary society, the prescribing of antipsychotics, particularly off-label use in elderly populations with dementia or in children and adolescents for behavioral issues, has raised ethical and medical concerns regarding overprescription and the risk of severe adverse effects. Furthermore, the subjective experience of taking antipsychotics—often described by patients as causing emotional blunting or cognitive dulling—has fueled advocacy for psychosocial interventions, peer support, and more personalized, patient-centered approaches to psychiatric care. The pharmaceutical industry's marketing practices and the financial burden of newer, patented atypical antipsychotics have also been subjects of ongoing scrutiny and health economics debates.